Expert Insights in Selecting Therapy for Chronic Hepatitis B
  • CME
  • CE

In this CME-certified activity, Tram T. Tran, MD, presents a series of topical case studies featuring patients with chronic hepatitis B, and discusses how our expert faculty chose to manage them.
Tram T. Tran, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.8 Nursing contact hours
Pharmacists: 0.75 contact hours (0.08 CEUs)
Released: December 15, 2017 Expiration: December 14, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the latest treatment guidelines when determining timing of treatment for patients with chronic hepatitis B
  • Integrate recently approved HBV therapies into patient management strategies
  • Select appropriate treatment for HBeAg-positive and HBeAg-negative patients with chronic hepatitis B based on individual patient factors

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Tram T. Tran, MD

Medical Director of Liver Transplant
Comprehensive Transplant Center
Cedars Sinai Medical Center
Professor of Medicine
Division of Gastroenterology
Geffen UCLA School of Medicine
Los Angeles, California

Tram T. Tran, MD, has disclosed that that she has received consulting fees, fees for non-CME/CE services, and funds for research support from Bristol-Myers Squibb and Gilead Sciences.

Staff

Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with chronic hepatitis B.

Goal

The goal of this activity is to improve clinicians’ competence in objectively evaluating the differences and similarities among available HBV agents and in selecting optimal therapy for each individual patient.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

This educational activity for 0.8 contact hour is provided by Postgraduate Institute for Medicine.

Pharmacist Continuing Education

Accreditation Statement

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0809-9999-17-1006-H01-P.

Type of Activity: Knowledge

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 15, 2017, through December 14, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Patients with hepatitis B may benefit from peginterferon if they need a limited duration of therapy, have genotype A HBV, or have hepatitis D coinfection.

Robert S. Brown, Jr., MD, MPH Released: May 21, 2018

Expert faculty members summarize key viral hepatitis studies from this important annual conference.

Released: April 30, 2018

Following recent updates to the AASLD HBV guidelines, what criteria determine optimal therapy for immune-active CHB?

Norah Terrault, MD, MPH Released: April 30, 2018

Listen to downloadable audio from a live Webinar in which Stefan Zeuzem, MD, assessed the clinical impact of new data reported at the Paris meeting and answered case questions from participants.

Stefan Zeuzem, MD Released: April 26, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC

PIM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and by the Accreditation Council for Pharmacy Education (ACPE). Additionally, PIM is an approved provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation (ANCC) and the California Board of Registered Nurses.

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Educational grant provided by:
Gilead Sciences

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?